Biofrontera reports preliminary revenue for the month of April 2021
May 06 2021 - 7:23AM
Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the
“Company”), an international biopharmaceutical company, today
reported preliminary, unaudited revenue for the month of April
2021.
The Company’s preliminary, unaudited revenue
from product sales in April 2021 amounted to approximately EUR
2,491 thousand, compared to EUR 492 thousand in April 2020, an
increase of 406%. Total revenue for the month of April 2020 was EUR
6,602 thousand, whereby April 2020 included a one-time down payment
of EUR 6,000 thousand from Maruho Co., Ltd as part of a license and
supply agreement.
Preliminary revenues from product sales in the
US were around EUR 1,821 thousand compared to EUR 333 thousand in
April 2020, an increase of 447%. In Germany, revenues from product
sales amounted to approximately EUR 441 thousand, compared to EUR
143 thousand in April 2020, an increase of 208%. In the rest of
Europe, the Company generated product sales of around EUR 229
thousand, compared to EUR 17 thousand in April 2020, a plus of
1,247%.
Preliminary unaudited
revenues
|
April |
January - April |
in EUR thousands |
2021 |
2020 |
2019 |
2021 |
2020 |
2019 |
USA |
1,821 |
333 |
1,767 |
5.631 |
4,513 |
6,939 |
Germany |
441 |
143 |
353 |
1,845 |
1,453 |
1,425 |
Europe (ex Germany) |
229 |
17 |
191 |
493 |
836 |
755 |
Total revenue from product
sales |
2,491 |
492 |
2,311 |
7,969 |
6,802 |
9,119 |
Revenues from R&D projects and license payments |
- |
6,110 |
44 |
- |
6,273 |
44 |
Total revenue |
2,491 |
6,602 |
2,355 |
7,969 |
13,075 |
9,163 |
For better comparability, the Company also
included the monthly sales performance before the pandemic in 2019.
Compared to 2019, total product sales in 2021 were up 8% in all
markets. In detail, April 2021 sales were up 3% in the U.S., 25% in
Germany and 20% in the rest of the European markets compared to
April 2019.
The sales increase compared to the previous year
already perceived since mid-March 2021, especially in our most
important sales market, the USA, continued strongly in April 2021.
This indicates a significant recovery of the COVID-19 situation in
the USA as well as in Germany - presumably also due to the high
vaccination rates.
-End-
Biofrontera AGPamela Keck, Head of Investor
Relationsir@biofrontera.com+49-214-87632-0
About
Biofrontera: Biofrontera AG is a
biopharmaceutical company specializing in the development and sale
of dermatological drugs and medical cosmetics.
The Germany-based company, with over 150
employees worldwide, develops and markets innovative products for
the care, protection and treatment of the skin. The company’s lead
product is the combination of Ameluz®, a topical prescription drug,
and medical device BF-RhodoLED® for the photodynamic therapy of
certain superficial skin cancers and their precursors. Ameluz® has
been marketed in the EU since 2012 and in the United States since
May 2016. In addition, the company markets the prescription
medication Xepi® for the treatment of impetigo in the United
States. In the EU, the company also sells the dermocosmetics series
Belixos®, which offers specialized care for damaged or diseased
skin.
Biofrontera is the first German founder-led
pharmaceutical company to receive a centralized European and a US
approval for a drug developed in-house. The Biofrontera Group was
founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is
listed on the Frankfurt Stock Exchange (Prime Standard) and on the
US NASDAQ.www.biofrontera.com.
Forward-Looking Statements: Certain statements
in this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995 regarding the
public offering and the intended use of proceeds from the
offering.
These statements may be identified by the use of
forward-looking words such as "anticipate," "believe," "forecast,"
"estimate" and "intend," among others. Such forward-looking
statements are based on the currently held beliefs and assumptions
of the management of Biofrontera AG, which are expressed in good
faith and, in their opinion, reasonable. Forward-looking statements
involve known and unknown risks, uncertainties and other factors,
which may cause the actual results, financial condition,
performance, or achievements of the Company, or industry results,
to differ materially from the results, financial condition,
performance or achievements expressed or implied by such
forward-looking statements. These risks, uncertainties and other
factors are set forth in the Registration Statement on Form F-1
filed with the SEC, including in the section "Risk Factors," and in
future reports filed with the SEC. Given these risks, uncertainties
and other factors, prospective investors are cautioned not to place
undue reliance on these forward-looking statements. The Company
does not undertake an obligation to update or revise any
forward-looking statement.
Biofrontera (NASDAQ:BFRA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biofrontera (NASDAQ:BFRA)
Historical Stock Chart
From Sep 2023 to Sep 2024